Search

Your search keyword '"Raouf, Sherif"' showing total 37 results
Start Over Author "Raouf, Sherif"
37 results on '"Raouf, Sherif"'

3. Trifluridine/Tipiracil in Metastatic Colorectal Cancer: A UK Multicenter Real-world Analysis on Efficacy, Safety, Predictive and Prognostic Factors

Author

Stavraka, Chara, Pouptsis, Athanasios, Synowiec, Alicja, Angelis, Vasileios, Satterthwaite, Liyana, Khan, Sam, Chauhan, Meera, Holden, Chloe, Young, Sally, Karampera, Christina, Martinou, Maria, Mills-Baldock, Tina, Baxter, Mark, Barry, Ainsley, Eccles, Bryony, Iveson, Timothy, Shiu, Kai-Keen, Hill, Mark, Abdel-Raouf, Sherif, Graham, Janet Shirley, Thomas, Anne, and Ross, Paul J.

Published
2021
Full Text
View/download PDF

4. FDG-PET/CT in colorectal cancer: potential for vascular-metabolic imaging to provide markers of prognosis

Author

Chen, Shih-hsin, Miles, Kenneth, Taylor, Stuart A., Ganeshan, Balaji, Rodriquez, Manuel, Fraioli, Francesco, Wan, Simon, Afaq, Asim, Shortman, Robert, Walls, Darren, Hoy, Luke, Endozo, Raymond, Bhargava, Aman, Hanson, Matthew, Huang, Joseph, Raouf, Sherif, Francis, Daren, Siddiqi, Shahab, Arulampalam, Tan, Sizer, Bruce, Machesney, Michael, Reay-Jones, Nicholas, Dindyal, Sanjay, Ng, Tony, and Groves, Ashley M

Published
2021
Full Text
View/download PDF

6. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial

Author

Shablack, Alaaeldin, O'Callaghan, Ann, Moody, (Margaret) Anne, Allen, Alex, Brewster, Alison, Brown, Alison, Mayer, Astrid, Davidson, Brian, Ton, Chan, Wilson, Charles, Lowdell, Charles, Rees, Charlotte, Baughan, Christopher, Barlow, Clare, Purcell, Colin, Smith, David, Tsang, David, Brown, Ewan, Walker, Georgina, Malik, Hassan, Cameron, Iain, Nolan, Luke, Hall, Marcia, Tomlinson, Marjorie, Hill, Mark, Peterson, Mark, Finch-Jones, Meg, Kumar, Nagappan, Karanjia, Nariman, Ali, Nasim, Heaton, Nigel, Ton, Nua Chan, Ross, Paul, Praseedom, Raaj, Thomas, Robert, Clive, Sally, Slater, Sarah, Smith, Sarah, Mudan, Satvinder, Bhattacharya, Satya, Essapen, Sharadah, Raouf, Sherif, Fenwick, Stephen, Cleator, Susan, Diamond, Tom, Potter, Vanessa, Bridgewater, John A, Pugh, Siân A, Maishman, Tom, Eminton, Zina, Mellor, Jane, Whitehead, Amy, Stanton, Louise, Radford, Michael, Corkhill, Andrea, Griffiths, Gareth O, Falk, Stephen, Valle, Juan W, O'Reilly, Derek, Siriwardena, Ajith K, Hornbuckle, Joanne, Rees, Myrddin, Iveson, Timothy J, Hickish, Tamas, Garden, O James, Cunningham, David, Maughan, Timothy S, and Primrose, John N

Published
2020
Full Text
View/download PDF

7. Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed colorectal cancer: the prospective Streamline C trial

Author

Evans, Ruth, Ball, Simon, Jannapureddy, Revanth, Mills-Baldock, Tina, Barhate, Kishor, Nagy, Zoltan, Raouf, Sherif, Aboagye, Akosa, Anand, Girija, Butawan, Rommel, Hadley, Elizabeth, Onajobi, Adesewa, Tarver, Kathryn, Nawaz, Tanjil, Norman, Catherine, Rich, Nathalie, Tulmuntaha, Sidra, Ahmed, Shafi, Lim, Louise, McKirdy, Fiona, Couture, Jenna, Ferdous, Shahanara, Julka, Payal, Mohammed, Ali, O'Shaughnessy, Terry, Ricketts, William, Jackson, Marie, Kay, Clive, Lowe, Andy, McGowan, Janet, Mohammed, Amjad, Robinson, Jon, Curry, Lara, Maheswaran, Sasithar, Ramesh, Subramanian, Riddle, Pippa, Balogun, Shaki, Campbell, Yvonne, Jeyadevan, Nelesh, Kavidasan, Aji, Locke, Imogen, Loke, Tuck-Kay, Olaleye, Ibiyemi, Collins, Clare, Green, Elizabeth, Prendergast, Colm, Win, Thida, Davis, Amy, Blakeway, Lyn, Gourtsoyianni, Sofia, Green, Adrian, Kelly-Morland, Christian, Naaseri, Sahar, Prezzi, Davide, Snell, David, Boisfer, Dorothee, Desai, Keyury, Hans, Balinder, Hans, Sophia, Ntala, Eleni, Alam, Adnam, Burke, Stephen, Bhowmik, Angshu, Bharwani, Nishat, Hanid, Gule, Honeyfield, Lesley, Stoycheva, Tina, Strickland, Nicola, Bazari, Farid, Beedham, Helen, De Los, Jane, Lauigan, Reyes, Limbu, Priya, Lucas, Nicola, O'Connor, Sally, Rhodes, Anita, Agoramoorthy, Laletha, Handousa, Martha, Jalloh, Abel, Stegner, Stefania, Wilson, Shanna, Birch, David, Chukundah, Suzanne, Phiri, Priscilla, Srirajaskanthan, Raj, Karapanagiotou, Eleni, Smith, Daniel, Syeed, Ferrial, van Someren, Chloe, Borgstein, Rudi, Roehrig, Jamila, Chao, David, Hurl, Lorraine, Gogbashian, Andrew, Nunes, Andre, Simcock, Ian, Stirling, James, Beable, Richard, Furneaux, Maureen, Gibbons, Nicola, Higginson, Antony, Curtis, Howard, Perry, Kitrick, Amadi, Anita, Hughes, Heather, Patel, Prital, Atkin, Gary, Elton, Colin, Karp, Stephen, Woodrow, Lisa, Yu, Dominic, Khan, Sajid, Rienhardt, Alistair, Datt, Pooja, Ilangovan, Rajapandian, Jenkins, Ian, Mahmud, Saba, Light, Teresa, Kellaway, Joanne, O'Callaghan, Ann, Partridge, William, Daniel, Amelia, Ekeowa, Ugo, Long, Michael, Russell, Peter, Scurr, Erica, Morgan, Veronica, Tunariu, Nina, Chang, Elizabeth, Hughes, Laura, Marwood, Ellice, Prior, Katie, Reddi, Meena, Sargus, Kara, Sharp, Abby, Beeston, Teresita, Isaac, Elizabeth, Jayme, Adoracion, Kalasthry, Jagadish, Piga, Wivijin, Rahman, Farzana, Weir, Shraddha, Austria, Aileen, Crosbie, James, Engledow, Alec, McCullogh, Jonathan, Obichere, Austen, Shiu, Kai-Keen, Wanstall, Christopher, Simeon, Celia, Smith, Amy, Bateman, Andrew, Breen, David, Davis, Liane, Everitt, Chris, Johnson, Alice, Nichols, Paul, Shepherd, Beth, Gilbert, Kayleigh, Verjee, Azmina, Saull, Michelle, Wilson, Jonathan, Adeniba, Rashidat, Conteh, Veronica, Howling, Sarah, Lock, Sara, Taylor, Stuart A, Mallett, Sue, Beare, Sandy, Bhatnagar, Gauraang, Blunt, Dominic, Boavida, Peter, Bridgewater, John, Clarke, Caroline S, Duggan, Marian, Ellis, Steve, Glynne-Jones, Robert, Goh, Vicky, Groves, Ashley M, Hameeduddin, Ayshea, Janes, Sam M, Johnston, Edward W, Koh, Dow-Mu, Miles, Anne, Morris, Stephen, Morton, Alison, Navani, Neal, O'Donohue, John, Oliver, Alfred, Padhani, Anwar R, Pardoe, Helen, Patel, Uday, Punwani, Shonit, Quinn, Laura, Rafiee, Hameed, Reczko, Krystyna, Rockall, Andrea G, Shahabuddin, Khawaja, Sidhu, Harbir S, Teague, Jonathan, Thaha, Mohamed A, Train, Matthew, van Ree, Katherine, Wijeyekoon, Sanjaya, and Halligan, Steve

Published
2019
Full Text
View/download PDF

8. Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed non-small-cell lung cancer: the prospective Streamline L trial

Author

Evans, Ruth, Shahabuddin, Khawaja, Jannapureddy, Revanth, Mills-Baldock, Tina, Barhate, Kishor, Nagy, Zoltan, Raouf, Sherif, Aboagye, Akosa, Anand, Girija, Butawan, Rommel, Hadley, Elizabeth, Onajobi, Adesewa, Thaha, Mohamed A, Nawaz, Tanjil, Norman, Catherine, Rich, Nathalie, Tulmuntaha, Sidra, Ahmed, Shafi, Lim, Louise, McKirdy, Fiona, Couture, Jenna, Ferdous, Shahanara, Julka, Payal, Mohammed, Ali, Pardoe, Helen, Wijeyekoon, Sanjaya, Van Ree, Katherine, Blunt, Dominic, Ricketts, William, Jackson, Marie, Kay, Clive, Lowe, Andy, McGowan, Janet, Mohammed, Amjad, Robinson, Jon, Curry, Lara, Maheswaran, Sasithar, Ramesh, Subramanian, Riddle, Pippa, Balogun, Shaki, Campbell, Yvonne, Jeyadevan, Nelesh, Kavidasan, Aji, Locke, Imogen, Loke, Tuck-Kay, Olaleye, Ibiyemi, Collins, Clare, Green, Elizabeth, Prendergast, Colm, Win, Thida, Davis, Amy, Blakeway, Lyn, Gourtsoyianni, Sofia, Green, Adrian, Kelly-Morland, Christian, Naaseri, Sahar, O'Donohue, John, Snell, David, Boisfer, Dorothee, Desai, Keyury, Hans, Balinder, Hans, Sophia, Ntala, Eleni, Alam, Adnam, Burke, Stephen, Train, Matthew, Bharwani, Nishat, Hanid, Gule, Honeyfield, Lesley, Stoycheva, Tina, Patel, Uday, Bazari, Farid, Beedham, Helen, De Los, Jane, Lauigan, Reyes, Limbu, Priya, Lucas, Nicola, O'Connor, Sally, Rhodes, Anita, Agoramoorthy, Laletha, Handousa, Martha, Jalloh, Abel, Stegner, Stefania, Wilson, Shanna, Birch, David, Chukundah, Suzanne, Phiri, Priscilla, Srirajaskanthan, Raj, Karapanagiotou, Eleni, Smith, Daniel, Syeed, Ferrial, van Someren, Chloe, Borgstein, Rudi, Roehrig, Jamila, Chao, David, Hurl, Lorraine, Gogbashian, Andrew, Nunes, Andre, Simcock, Ian, Stirling, James, Beable, Richard, Furneaux, Maureen, Gibbons, Nicola, Higginson, Antony, Curtis, Howard, Perry, Kitrick, Amadi, Anita, Hughes, Heather, Patel, Prital, Atkin, Gary, Elton, Colin, Karp, Stephen, Woodrow, Lisa, Yu, Dominic, Khan, Sajid, Rienhardt, Alistair, Datt, Pooja, Ilangovan, Rajapandian, Jenkins, Ian, Mahmud, Saba, Light, Teresa, Kellaway, Joanne, O'Callaghan, Ann, Partridge, William, Daniel, Amelia, Ekeowa, Ugo, Long, Michael, Scurr, Erica, Morgan, Veronica, Tunariu, Nina, Chang, Elizabeth, Hughes, Laura, Marwood, Ellice, Prior, Katie, Reddi, Meena, Sargus, Kara, Sharp, Abby, Beeston, Teresita, Isaac, Elizabeth, Jayme, Adoracion, Kalasthry, Jagadish, Piga, Wivijin, Rahman, Farzana, Weir, Shraddha, Austria, Aileen, Crosbie, James, Engledow, Alec, McCullogh, Jonathan, Obichere, Austen, Shiu, Kai-Keen, Wanstall, Christopher, Simeon, Celia, Smith, Amy, Bateman, Andrew, Breen, David, Davis, Liane, Everitt, Chris, Johnson, Alice, Nichols, Paul, Shepherd, Beth, Gilbert, Kayleigh, Verjee, Azmina, Saull, Michelle, Wilson, Jonathan, Adeniba, Rashidat, Conteh, Veronica, Howling, Sarah, Taylor, Stuart A, Mallett, Sue, Ball, Simon, Beare, Sandy, Bhatnagar, Gauraang, Bhowmik, Angshu, Boavida, Peter, Bridgewater, John, Clarke, Caroline S, Duggan, Marian, Ellis, Steve, Glynne-Jones, Robert, Goh, Vicky, Groves, Ashley M, Hameeduddin, Ayshea, Janes, Sam M, Johnston, Edward W, Koh, Dow-Mu, Lock, Sara, Miles, Anne, Morris, Stephen, Morton, Alison, Navani, Neal, Oliver, Alfred, O'Shaughnessy, Terry, Padhani, Anwar R, Prezzi, David, Punwani, Shonit, Quinn, Laura, Rafiee, Hameed, Reczko, Krystyna, Rockall, Andrea G, Russell, Peter, Sidhu, Harbir S, Strickland, Nicola, Tarver, Kathryn, Teague, Jonathan, and Halligan, Steve

Published
2019
Full Text
View/download PDF

9. Correction to: FDG-PET/CT in colorectal cancer: potential for vascular-metabolic imaging to provide markers of prognosis

Author

Chen, Shih-Hsin, Miles, Kenneth, Taylor, Stuart A., Ganeshan, Balaji, Rodriquez, Manuel, Fraioli, Francesco, Wan, Simon, Afaq, Asim, Shortman, Robert, Walls, Darren, Hoy, Luke, Endozo, Raymond, Bhargava, Aman, Hanson, Matthew, Huang, Joseph, Raouf, Sherif, Francis, Daren, Siddiqi, Shahab, Arulampalam, Tan, Sizer, Bruce, Machesney, Michael, Reay-Jones, Nicholas, Dindyal, Sanjay, Ng, Tony, and Groves, Ashley M.

Published
2022
Full Text
View/download PDF

10. SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer

Author

Robles-Zurita, José, Boyd, Kathleen A., Briggs, Andrew H., Iveson, Timothy, Kerr, Rachel S., Saunders, Mark P., Cassidy, Jim, Hollander, Niels Henrik, Tabernero, Josep, Segelov, Eva, Glimelius, Bengt, Harkin, Andrea, Allan, Karen, McQueen, John, Pearson, Sarah, Waterston, Ashita, Medley, Louise, Wilson, Charles, Ellis, Richard, Essapen, Sharadah, Dhadda, Amandeep S., Hughes, Rob, Falk, Stephen, Raouf, Sherif, Rees, Charlotte, Olesen, Rene K, Propper, David, Bridgewater, John, Azzabi, Ashraf, Farrugia, David, Webb, Andrew, Cunningham, David, Hickish, Tamas, Weaver, Andrew, Gollins, Simon, Wasan, Harpreet S, and Paul, James

Published
2018
Full Text
View/download PDF

12. Is management of rectal cancer using watch-and-wait approach feasible, safe, and effective in a publicly funded general hospital?

Author

Mansuri, Ahmer, primary, Tan, Ky Lyn, additional, Kaul, Sandeep, additional, Rao, Christopher, additional, Mane, Rashi, additional, Khan, Ameer, additional, Hussain, Shahvaiz, additional, Banerjee, Saswata, additional, Boulton, Richard, additional, Bhargava, Aman, additional, Huang, Joseph, additional, Matthew, Hanson, additional, Raouf, Sherif, additional, Ball, Simon, additional, and Rajendran, Nirooshun, additional

Published
2022
Full Text
View/download PDF

13. Conservative Treatment versus Percutaneous Vertebroplasty for Osteoporotic Stable Dorsolumbar Vertebral Fracture.

Author

Hasanin, Samy, Abdel-Raouf, Sherif, Haroon, Hossam Ahmed Tawfiq, and El Zohiery, Mustafa

Subjects
*VERTEBRAE injuries, *VERTEBRAL fractures, *VERTEBROPLASTY, *CONSERVATIVE treatment, *BONE fractures, *COMPRESSION fractures
Abstract

Introduction: Osteoporosis is rapidly becoming a significant healthcare burden in a population aged over 69 years. Dorsolumbar osteoporotic compression fractures are common between these patients. Percutaneous vertebroplasty (PVP) is considered a minimally invasive method to relieve the pain secondary to vertebral fracture. Aim of study: This study aimed to compare the role of conservative treatment to percutaneous vertebroplasty that is used to treat stable dorsolumbar vertebral fractures in osteoporotic patients. Patients and Methods: This prospective cohort study was carried out in the Department of Neurosurgery, School of Medicine, Zagazig University Hospitals at Gamal Abdelnaser Insurance Hospital in Alexandria. The study included thirtysix patients with osteoporosis. 18 people have received treatment for their spinal compression fractures by conservative management and eighteen patients have been treated by percutaneous vertebroplasty. Results: The most common level of fracture was thoraco-lumbar junction (61% in both groups). Single fractures were more common than double fractures in both groups. Patients in PVP had significantly improved clinical outcomes of VAS of the back and leg and ODI scores at 6 months follow-up compared to those at the conservative group. There was marked improvement in ODI and VAS score immediate post-operative and six-month follow-up in PVP group with a high statistically significant difference. Conclusion: Percutaneous compared to conservative treatment, vertebroplasty can offer better clinical and radiological results for individuals with osteoporotic vertebral fractures. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

14. Correction to: FDG-PET/CT in colorectal cancer: potential for vascular-metabolic imaging to provide markers of prognosis

Author

Chen, Shih-Hsin, primary, Miles, Kenneth, additional, Taylor, Stuart A., additional, Ganeshan, Balaji, additional, Rodriquez, Manuel, additional, Fraioli, Francesco, additional, Wan, Simon, additional, Afaq, Asim, additional, Shortman, Robert, additional, Walls, Darren, additional, Hoy, Luke, additional, Endozo, Raymond, additional, Bhargava, Aman, additional, Hanson, Matthew, additional, Huang, Joseph, additional, Raouf, Sherif, additional, Francis, Daren, additional, Siddiqi, Shahab, additional, Arulampalam, Tan, additional, Sizer, Bruce, additional, Machesney, Michael, additional, Reay-Jones, Nicholas, additional, Dindyal, Sanjay, additional, Ng, Tony, additional, and Groves, Ashley M., additional

Published
2021
Full Text
View/download PDF

15. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT) : an international, randomised, phase 3, non-inferiority trial

Author

Iveson, Timothy J., Kerr, Rachel S., Saunders, Mark P., Cassidy, Jim, Hollander, Niels Henrik, Tabernero, Josep, Haydon, Andrew, Glimelius, Bengt, Harkin, Andrea, Allan, Karen, McQueen, John, Scudder, Claire, Boyd, Kathleen A., Briggs, Andrew, Waterston, Ashita, Medley, Louise, Wilson, Charles, Ellis, Richard, Essapen, Sharadah, Dhadda, Amandeep S., Harrison, Mark, Falk, Stephen, Raouf, Sherif, Rees, Charlotte, Olesen, Rene K., Propper, David, Bridgewater, John, Azzabi, Ashraf, Farrugia, David, Webb, Andrew, Cunningham, David, Hickish, Tamas, Weaver, Andrew, Gollins, Simon, Wasan, Harpreet S.., Paul, James, and Universitat Autònoma de Barcelona

Subjects
Male, Time Factors, Organoplatinum Compounds, Leucovorin, Peripheral Nervous System Diseases, Adenocarcinoma, Middle Aged, Disease-Free Survival, Oxaliplatin, Survival Rate, Antineoplastic Combined Chemotherapy Protocols, Quality of Life, Chemotherapy, Humans, Female, Fluorouracil, Colorectal Neoplasms, Capecitabine, Aged, Neoplasm Staging
Abstract

6 months of oxaliplatin-containing chemotherapy is usually given as adjuvant treatment for stage 3 colorectal cancer. We investigated whether 3 months of oxaliplatin-containing chemotherapy would be non-inferior to the usual 6 months of treatment. The SCOT study was an international, randomised, phase 3, non-inferiority trial done at 244 centres. Patients aged 18 years or older with high-risk stage II and stage III colorectal cancer underwent central randomisation with minimisation for centre, choice of regimen, sex, disease site, N stage, T stage, and the starting dose of capecitabine. Patients were assigned (1:1) to receive 3 months or 6 months of adjuvant oxaliplatin-containing chemotherapy. The chemotherapy regimens could consist of CAPOX (capecitabine and oxaliplatin) or FOLFOX (bolus and infused fluorouracil with oxaliplatin). The regimen was selected before randomisation in accordance with choices of the patient and treating physician. The primary study endpoint was disease-free survival and the non-inferiority margin was a hazard ratio of 1·13. The primary analysis was done in the intention-to-treat population and safety was assessed in patients who started study treatment. This trial is registered with ISRCTN, number ISRCTN59757862, and follow-up is continuing. 6088 patients underwent randomisation between March 27, 2008, and Nov 29, 2013. The intended treatment was FOLFOX in 1981 patients and CAPOX in 4107 patients. 3044 patients were assigned to 3 month group and 3044 were assigned to 6 month group. Nine patients in the 3 month group and 14 patients in the 6 month group did not consent for their data to be used, leaving 3035 patients in the 3 month group and 3030 patients in the 6 month group for the intention-to-treat analyses. At the cutoff date for analysis, there had been 1482 disease-free survival events, with 740 in the 3 month group and 742 in the 6 month group. 3 year disease-free survival was 76·7% (95% CI 75·1-78·2) for the 3 month group and 77·1% (75·6-78·6) for the 6 month group, giving a hazard ratio of 1·006 (0·909-1·114, test for non-inferiority p=0·012), significantly below the non-inferiority margin. Peripheral neuropathy of grade 2 or worse was more common in the 6 month group (237 [58%] of 409 patients for the subset with safety data) than in the 3 month group (103 [25%] of 420) and was long-lasting and associated with worse quality of life. 1098 serious adverse events were reported (492 reports in the 3 month group and 606 reports in the 6 month group) and 32 treatment-related deaths occurred (16 in each group). In the whole study population, 3 months of oxaliplatin-containing adjuvant chemotherapy was non-inferior to 6 months of the same therapy for patients with high-risk stage II and stage III colorectal cancer and was associated with reduced toxicity and improved quality of life. Despite the fact the study was underpowered, these data suggest that a shorter duration leads to similar survival outcomes with better quality of life and thus might represent a new standard of care. Medical Research Council, Swedish Cancer Society, NETSCC, and Cancer Research UK.

Published
2021

16. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial

Author

Bridgewater, John A, primary, Pugh, Siân A, additional, Maishman, Tom, additional, Eminton, Zina, additional, Mellor, Jane, additional, Whitehead, Amy, additional, Stanton, Louise, additional, Radford, Michael, additional, Corkhill, Andrea, additional, Griffiths, Gareth O, additional, Falk, Stephen, additional, Valle, Juan W, additional, O'Reilly, Derek, additional, Siriwardena, Ajith K, additional, Hornbuckle, Joanne, additional, Rees, Myrddin, additional, Iveson, Timothy J, additional, Hickish, Tamas, additional, Garden, O James, additional, Cunningham, David, additional, Maughan, Timothy S, additional, Primrose, John N, additional, Shablack, Alaaeldin, additional, O'Callaghan, Ann, additional, Moody, (Margaret) Anne, additional, Allen, Alex, additional, Brewster, Alison, additional, Brown, Alison, additional, Mayer, Astrid, additional, Davidson, Brian, additional, Ton, Chan, additional, Wilson, Charles, additional, Lowdell, Charles, additional, Rees, Charlotte, additional, Baughan, Christopher, additional, Barlow, Clare, additional, Purcell, Colin, additional, Smith, David, additional, Tsang, David, additional, Brown, Ewan, additional, Walker, Georgina, additional, Malik, Hassan, additional, Cameron, Iain, additional, Nolan, Luke, additional, Hall, Marcia, additional, Tomlinson, Marjorie, additional, Hill, Mark, additional, Peterson, Mark, additional, Finch-Jones, Meg, additional, Kumar, Nagappan, additional, Karanjia, Nariman, additional, Ali, Nasim, additional, Heaton, Nigel, additional, Ton, Nua Chan, additional, Ross, Paul, additional, Praseedom, Raaj, additional, Thomas, Robert, additional, Clive, Sally, additional, Slater, Sarah, additional, Smith, Sarah, additional, Mudan, Satvinder, additional, Bhattacharya, Satya, additional, Essapen, Sharadah, additional, Raouf, Sherif, additional, Fenwick, Stephen, additional, Cleator, Susan, additional, Diamond, Tom, additional, and Potter, Vanessa, additional

Published
2020
Full Text
View/download PDF

17. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial

Author

Jones, Robert P, Psarelli, Eftychia-Eirini, Jackson, Richard, Ghaneh, Paula, Halloran, Christopher M, Palmer, Daniel H, Campbell, Fiona, Valle, Juan W, Faluyi, Olusola, O'Reilly, Derek A, Cunningham, David, Wadsley, Jonathan, Darby, Suzanne, Meyer, Tim, Gillmore, Roopinder, Anthoney, Alan, Lind, Pehr, Glimelius, Bengt, Falk, Stephen, Izbicki, Jakob R, Middleton, Gary William, Cummins, Sebastian, Ross, Paul J, Wasan, Harpreet, McDonald, Alec, Crosby, Tom, Ting, Yuk, Patel, Kinnari, Sherriff, David, Soomal, Rubin, Borg, David, Sothi, Sharmila, Hammel, Pascal, Lerch, Markus M, Mayerle, Julia, Tjaden, Christine, Strobel, Oliver, Hackert, Thilo, Buchler, Markus W, Neoptolemos, John P, Hill, Mark, Corrie, Pippa, Hickish, Tamas, Napier, Mark, Slater, Sarah, Valle, Juan, Shablak, Alaaeldin, Cunnell, Michelle, Guimbaud, Rosine, Roques, Tom, Iveson, Tim, Jamil, Arshad, Robinson, Angus, Garcia-Alonso, Angel, Chang, David, Tsang, David, Wadd, Nick, Wall, Lucy, Nielsen, Niels Hilmer, Lerch, Markus, Mehta, Ajay, Sivaramalingam, Muthiah, Fyfe, David, Osborne, Richard, Blesing, Claire, Bulusu, Venkata Ramesh, Rathbone, Emma, Seitz, Jean-Francois, Beaumont, Erica, Dernedde, Ulrike, McAdam, Karen, Dimopoulos, Prokopios, Cominos, Mathilda, Askill, Colin, Piwowar, Andrzej, Bachet, Jean-Baptiste, Sumpter, Kate, Raouf, Sherif, Nicoll, Jonathan, Rees, Charlotte, Dhinakaran, Kathirvelu, Haux, Johan, Bengrine-Lefevre, Leila, Terrebonne, Eric, Shankland, Catherine, Palmer, Cheryl, Medley, Louise, Toy, Elizabeth, Kaur, Jasvinder, Gupta, Kamalnayan, Cheeseman, Sue, Patterson, Daniel, Candish, Charles, Thompson, Joyce, Coxon, Fareeda, Connolly, Caroline, McPhail, Neil, Williams, Rachel, Flygare, Petra, Elmlund, Mattias, Artru, Pascal, Millat, Bertrand, and Canc, European Study Grp Pancreatic

Subjects
medicine.medical_specialty, Chemotherapy, Randomization, business.industry, medicine.medical_treatment, 030230 surgery, medicine.disease, Gastroenterology, Gemcitabine, law.invention, Capecitabine, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, 030220 oncology & carcinogenesis, Internal medicine, Pancreatic cancer, medicine, Carcinoma, Surgery, Prospective cohort study, business, medicine.drug
Abstract

Importance The patterns of disease recurrence after resection of pancreatic ductal adenocarcinoma with adjuvant chemotherapy remain unclear. Objective To define patterns of recurrence after adjuvant chemotherapy and the association with survival. Design, Setting, and Participants Prospectively collected data from the phase 3 European Study Group for Pancreatic Cancer 4 adjuvant clinical trial, an international multicenter study. The study included 730 patients who had resection and adjuvant chemotherapy for pancreatic cancer. Data were analyzed between July 2017 and May 2019. Interventions Randomization to adjuvant gemcitabine or gemcitabine plus capecitabine. Main Outcomes and Measures Overall survival, recurrence, and sites of recurrence. Results Of the 730 patients, median age was 65 years (range 37-81 years), 414 were men (57%), and 316 were women (43%). The median follow-up time from randomization was 43.2 months (95% CI, 39.7-45.5 months), with overall survival from time of surgery of 27.9 months (95% CI, 24.8-29.9 months) with gemcitabine and 30.2 months (95% CI, 25.8-33.5 months) with the combination (HR, 0.81; 95% CI, 0.68-0.98;P = .03). The 5-year survival estimates were 17.1% (95% CI, 11.6%-23.5%) and 28.0% (22.0%-34.3%), respectively. Recurrence occurred in 479 patients (65.6%); another 78 patients (10.7%) died without recurrence. Local recurrence occurred at a median of 11.63 months (95% CI, 10.05-12.19 months), significantly different from those with distant recurrence with a median of 9.49 months (95% CI, 8.44-10.71 months) (HR, 1.21; 95% CI, 1.01-1.45;P = .04). Following recurrence, the median survival was 9.36 months (95% CI, 8.08-10.48 months) for local recurrence and 8.94 months (95% CI, 7.82-11.17 months) with distant recurrence (HR, 0.89; 95% CI, 0.73-1.09;P = .27). The median overall survival of patients with distant-only recurrence (23.03 months; 95% CI, 19.55-25.85 months) or local with distant recurrence (23.82 months; 95% CI, 17.48-28.32 months) was not significantly different from those with only local recurrence (24.83 months; 95% CI, 22.96-27.63 months) (P = .85 andP = .35, respectively). Gemcitabine plus capecitabine had a 21% reduction of death following recurrence compared with monotherapy (HR, 0.79; 95% CI, 0.64-0.98;P = .03). Conclusions and Relevance There were no significant differences between the time to recurrence and subsequent and overall survival between local and distant recurrence. Pancreatic cancer behaves as a systemic disease requiring effective systemic therapy after resection. Trial Registration ClinicalTrials.gov identifier:NCT00058201, EudraCT 2007-004299-38, and ISRCTN 96397434.

Published
2019

18. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial

Author

Iveson, Timothy J., Kerr, Rachel S., Saunders, Mark P., Cassidy, Jim, Hollander, Niels Henrik, Tabernero, Josep, Haydon, Andrew, Glimelius, Bengy, Harkin, Andrea, Allan, Karen, McQueen, John, Scudder, Claire, Boyd, Kathleen Anne, Briggs, Andrew, Waterston, Ashita, Medley, Louise, Wilson, Charles, Ellis, Richard, Essapen, Sharadah, Dhadda, Amandeep S., Harrison, Mark, Falk, Stephen, Raouf, Sherif, Rees, Charlotte, Olesen, Rene K., Propper, David, Bridgewater, John, Azzabi, Ashraf, Farrugia, David, Webb, Andrew, Cunningham, David, Hickish, Tamas, Weaver, Andrew, Gollins, Simon, Wasan, Harpreet S., and Paul, James

Subjects
Male, Cancer och onkologi, Time Factors, Organoplatinum Compounds, Leucovorin, Peripheral Nervous System Diseases, Adenocarcinoma, Middle Aged, Disease-Free Survival, Oxaliplatin, Survival Rate, Chemotherapy, Adjuvant, Cancer and Oncology, Antineoplastic Combined Chemotherapy Protocols, Quality of Life, Humans, Female, Fluorouracil, Colorectal Neoplasms, Capecitabine, Aged, Neoplasm Staging
Abstract

Background: 6 months of oxaliplatin-containing chemotherapy is usually given as adjuvant treatment for stage 3 colorectal cancer. We investigated whether 3 months of oxaliplatin-containing chemotherapy would be non-inferior to the usual 6 months of treatment. Methods: The SCOT study was an international, randomised, phase 3, non-inferiority trial done at 244 centres. Patients aged 18 years or older with high-risk stage II and stage III colorectal cancer underwent central randomisation with minimisation for centre, choice of regimen, sex, disease site, N stage, T stage, and the starting dose of capecitabine. Patients were assigned (1:1) to receive 3 months or 6 months of adjuvant oxaliplatin-containing chemotherapy. The chemotherapy regimens could consist of CAPOX (capecitabine and oxaliplatin) or FOLFOX (bolus and infused fluorouracil with oxaliplatin). The regimen was selected before randomisation in accordance with choices of the patient and treating physician. The primary study endpoint was disease-free survival and the non-inferiority margin was a hazard ratio of 1·13. The primary analysis was done in the intention-to-treat population and safety was assessed in patients who started study treatment. This trial is registered with ISRCTN, number ISRCTN59757862, and follow-up is continuing. Findings: 6088 patients underwent randomisation between March 27, 2008, and Nov 29, 2013. The intended treatment was FOLFOX in 1981 patients and CAPOX in 4107 patients. 3044 patients were assigned to 3 month group and 3044 were assigned to 6 month group. Nine patients in the 3 month group and 14 patients in the 6 month group did not consent for their data to be used, leaving 3035 patients in the 3 month group and 3030 patients in the 6 month group for the intention-to-treat analyses. At the cutoff date for analysis, there had been 1482 disease-free survival events, with 740 in the 3 month group and 742 in the 6 month group. 3 year disease-free survival was 76·7% (95% CI 75·1–78·2) for the 3 month group and 77·1% (75·6–78·6) for the 6 month group, giving a hazard ratio of 1·006 (0·909–1·114, test for non-inferiority p=0·012), significantly below the non-inferiority margin. Peripheral neuropathy of grade 2 or worse was more common in the 6 month group (237 [58%] of 409 patients for the subset with safety data) than in the 3 month group (103 [25%] of 420) and was long-lasting and associated with worse quality of life. 1098 serious adverse events were reported (492 reports in the 3 month group and 606 reports in the 6 month group) and 32 treatment-related deaths occurred (16 in each group). Interpretation: In the whole study population, 3 months of oxaliplatin-containing adjuvant chemotherapy was non-inferior to 6 months of the same therapy for patients with high-risk stage II and stage III colorectal cancer and was associated with reduced toxicity and improved quality of life. Despite the fact the study was underpowered, these data suggest that a shorter duration leads to similar survival outcomes with better quality of life and thus might represent a new standard of care. Funding: Medical Research Council, Swedish Cancer Society, NETSCC, and Cancer Research UK.

Published
2019
Full Text
View/download PDF

19. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma : A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial

Author

Jones, Robert P., Psarelli, Eftychia-Eirini, Jackson, Richard, Ghaneh, Paula, Halloran, Christopher M., Palmer, Daniel H., Campbell, Fiona, Valle, Juan W., Faluyi, Olusola, O'Reilly, Derek A., Cunningham, David, Wadsley, Jonathan, Darby, Suzanne, Meyer, Tim, Gillmore, Roopinder, Anthoney, Alan, Lind, Pehr, Glimelius, Bengt, Falk, Stephen, Izbicki, Jakob R., Middleton, Gary William, Cummins, Sebastian, Ross, Paul J., Wasan, Harpreet, McDonald, Alec, Crosby, Tom, Ting, Yuk, Patel, Kinnari, Sherriff, David, Soomal, Rubin, Borg, David, Sothi, Sharmila, Hammel, Pascal, Lerch, Markus M., Mayerle, Julia, Tjaden, Christine, Strobel, Oliver, Hackert, Thilo, Buchler, Markus W., Neoptolemos, John P., Hill, Mark, Corrie, Pippa, Hickish, Tamas, Napier, Mark, Slater, Sarah, Valle, Juan, Shablak, Alaaeldin, Cunnell, Michelle, Guimbaud, Rosine, Roques, Tom, Iveson, Tim, Jamil, Arshad, Robinson, Angus, Garcia-Alonso, Angel, Chang, David, Tsang, David, Wadd, Nick, Wall, Lucy, Nielsen, Niels Hilmer, Lerch, Markus, Mehta, Ajay, Sivaramalingam, Muthiah, Fyfe, David, Osborne, Richard, Blesing, Claire, Bulusu, Venkata Ramesh, Rathbone, Emma, Seitz, Jean-Francois, Beaumont, Erica, Dernedde, Ulrike, McAdam, Karen, Dimopoulos, Prokopios, Cominos, Mathilda, Askill, Colin, Piwowar, Andrzej, Bachet, Jean-Baptiste, Sumpter, Kate, Raouf, Sherif, Nicoll, Jonathan, Rees, Charlotte, Dhinakaran, Kathirvelu, Haux, Johan, Bengrine-Lefevre, Leila, Terrebonne, Eric, Shankland, Catherine, Palmer, Cheryl, Medley, Louise, Toy, Elizabeth, Kaur, Jasvinder, Gupta, Kamalnayan, Cheeseman, Sue, Patterson, Daniel, Candish, Charles, Thompson, Joyce, Coxon, Fareeda, Connolly, Caroline, McPhail, Neil, Williams, Rachel, Flygare, Petra, Elmlund, Mattias, Artru, Pascal, Millat, Bertrand, Jones, Robert P., Psarelli, Eftychia-Eirini, Jackson, Richard, Ghaneh, Paula, Halloran, Christopher M., Palmer, Daniel H., Campbell, Fiona, Valle, Juan W., Faluyi, Olusola, O'Reilly, Derek A., Cunningham, David, Wadsley, Jonathan, Darby, Suzanne, Meyer, Tim, Gillmore, Roopinder, Anthoney, Alan, Lind, Pehr, Glimelius, Bengt, Falk, Stephen, Izbicki, Jakob R., Middleton, Gary William, Cummins, Sebastian, Ross, Paul J., Wasan, Harpreet, McDonald, Alec, Crosby, Tom, Ting, Yuk, Patel, Kinnari, Sherriff, David, Soomal, Rubin, Borg, David, Sothi, Sharmila, Hammel, Pascal, Lerch, Markus M., Mayerle, Julia, Tjaden, Christine, Strobel, Oliver, Hackert, Thilo, Buchler, Markus W., Neoptolemos, John P., Hill, Mark, Corrie, Pippa, Hickish, Tamas, Napier, Mark, Slater, Sarah, Valle, Juan, Shablak, Alaaeldin, Cunnell, Michelle, Guimbaud, Rosine, Roques, Tom, Iveson, Tim, Jamil, Arshad, Robinson, Angus, Garcia-Alonso, Angel, Chang, David, Tsang, David, Wadd, Nick, Wall, Lucy, Nielsen, Niels Hilmer, Lerch, Markus, Mehta, Ajay, Sivaramalingam, Muthiah, Fyfe, David, Osborne, Richard, Blesing, Claire, Bulusu, Venkata Ramesh, Rathbone, Emma, Seitz, Jean-Francois, Beaumont, Erica, Dernedde, Ulrike, McAdam, Karen, Dimopoulos, Prokopios, Cominos, Mathilda, Askill, Colin, Piwowar, Andrzej, Bachet, Jean-Baptiste, Sumpter, Kate, Raouf, Sherif, Nicoll, Jonathan, Rees, Charlotte, Dhinakaran, Kathirvelu, Haux, Johan, Bengrine-Lefevre, Leila, Terrebonne, Eric, Shankland, Catherine, Palmer, Cheryl, Medley, Louise, Toy, Elizabeth, Kaur, Jasvinder, Gupta, Kamalnayan, Cheeseman, Sue, Patterson, Daniel, Candish, Charles, Thompson, Joyce, Coxon, Fareeda, Connolly, Caroline, McPhail, Neil, Williams, Rachel, Flygare, Petra, Elmlund, Mattias, Artru, Pascal, and Millat, Bertrand

Abstract

Importance: The patterns of disease recurrence after resection of pancreatic ductal adenocarcinoma with adjuvant chemotherapy remain unclear. Objective: To define patterns of recurrence after adjuvant chemotherapy and the association with survival. Design, Setting, and Participants: Prospectively collected data from the phase 3 European Study Group for Pancreatic Cancer 4 adjuvant clinical trial, an international multicenter study. The study included 730 patients who had resection and adjuvant chemotherapy for pancreatic cancer. Data were analyzed between July 2017 and May 2019. Interventions: Randomization to adjuvant gemcitabine or gemcitabine plus capecitabine. Main Outcomes and Measures: Overall survival, recurrence, and sites of recurrence. Results: Of the 730 patients, median age was 65 years (range 37-81 years), 414 were men (57%), and 316 were women (43%). The median follow-up time from randomization was 43.2 months (95% CI, 39.7-45.5 months), with overall survival from time of surgery of 27.9 months (95% CI, 24.8-29.9 months) with gemcitabine and 30.2 months (95% CI, 25.8-33.5 months) with the combination (HR, 0.81; 95% CI, 0.68-0.98; P=.03). The 5-year survival estimates were 17.1% (95% CI, 11.6%-23.5%) and 28.0% (22.0%-34.3%), respectively. Recurrence occurred in 479 patients (65.6%); another 78 patients (10.7%) died without recurrence. Local recurrence occurred at a median of 11.63 months (95% CI, 10.05-12.19 months), significantly different from those with distant recurrence with a median of 9.49 months (95% CI, 8.44-10.71 months) (HR, 1.21; 95% CI, 1.01-1.45; P=.04). Following recurrence, the median survival was 9.36 months (95% CI, 8.08-10.48 months) for local recurrence and 8.94 months (95% CI, 7.82-11.17 months) with distant recurrence (HR, 0.89; 95% CI, 0.73-1.09; P=.27). The median overall survival of patients with distant-only recurrence (23.03 months; 95% CI, 19.55-25.85 months) or local with distant recurrence (23.82 months; 95% CI, 17.48-28.32

Published
2019
Full Text
View/download PDF

20. ACORN: Observational Study of Bevacizumab in Combination With First-Line Chemotherapy for Treatment of Metastatic Colorectal Cancer in the UK

Author

Khakoo, Shelize, primary, Chau, Ian, additional, Pedley, Ian, additional, Ellis, Richard, additional, Steward, Will, additional, Harrison, Mark, additional, Baijal, Shobhit, additional, Tahir, Saad, additional, Ross, Paul, additional, Raouf, Sherif, additional, Ograbek, Agnes, additional, and Cunningham, David, additional

Published
2019
Full Text
View/download PDF

21. 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT

Author

Iveson, Timothy, primary, Boyd, Kathleen A, additional, Kerr, Rachel S, additional, Robles-Zurita, Jose, additional, Saunders, Mark P, additional, Briggs, Andrew H, additional, Cassidy, Jim, additional, Hollander, Niels Henrik, additional, Tabernero, Josep, additional, Haydon, Andrew, additional, Glimelius, Bengt, additional, Harkin, Andrea, additional, Allan, Karen, additional, McQueen, John, additional, Pearson, Sarah, additional, Waterston, Ashita, additional, Medley, Louise, additional, Wilson, Charles, additional, Ellis, Richard, additional, Essapen, Sharadah, additional, Dhadda, Amandeep S, additional, Harrison, Mark, additional, Falk, Stephen, additional, Raouf, Sherif, additional, Rees, Charlotte, additional, Olesen, Rene K, additional, Propper, David, additional, Bridgewater, John, additional, Azzabi, Ashraf, additional, Farrugia, David, additional, Webb, Andrew, additional, Cunningham, David, additional, Hickish, Tamas, additional, Weaver, Andrew, additional, Gollins, Simon, additional, Wasan, Harpreet, additional, and Paul, James, additional

Published
2019
Full Text
View/download PDF

22. Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed colorectal cancer: the prospective Streamline C trial

Author

Taylor, Stuart A, primary, Mallett, Sue, additional, Beare, Sandy, additional, Bhatnagar, Gauraang, additional, Blunt, Dominic, additional, Boavida, Peter, additional, Bridgewater, John, additional, Clarke, Caroline S, additional, Duggan, Marian, additional, Ellis, Steve, additional, Glynne-Jones, Robert, additional, Goh, Vicky, additional, Groves, Ashley M, additional, Hameeduddin, Ayshea, additional, Janes, Sam M, additional, Johnston, Edward W, additional, Koh, Dow-Mu, additional, Miles, Anne, additional, Morris, Stephen, additional, Morton, Alison, additional, Navani, Neal, additional, O'Donohue, John, additional, Oliver, Alfred, additional, Padhani, Anwar R, additional, Pardoe, Helen, additional, Patel, Uday, additional, Punwani, Shonit, additional, Quinn, Laura, additional, Rafiee, Hameed, additional, Reczko, Krystyna, additional, Rockall, Andrea G, additional, Shahabuddin, Khawaja, additional, Sidhu, Harbir S, additional, Teague, Jonathan, additional, Thaha, Mohamed A, additional, Train, Matthew, additional, van Ree, Katherine, additional, Wijeyekoon, Sanjaya, additional, Halligan, Steve, additional, Evans, Ruth, additional, Ball, Simon, additional, Jannapureddy, Revanth, additional, Mills-Baldock, Tina, additional, Barhate, Kishor, additional, Nagy, Zoltan, additional, Raouf, Sherif, additional, Aboagye, Akosa, additional, Anand, Girija, additional, Butawan, Rommel, additional, Hadley, Elizabeth, additional, Onajobi, Adesewa, additional, Tarver, Kathryn, additional, Nawaz, Tanjil, additional, Norman, Catherine, additional, Rich, Nathalie, additional, Tulmuntaha, Sidra, additional, Ahmed, Shafi, additional, Lim, Louise, additional, McKirdy, Fiona, additional, Couture, Jenna, additional, Ferdous, Shahanara, additional, Julka, Payal, additional, Mohammed, Ali, additional, O'Shaughnessy, Terry, additional, Ricketts, William, additional, Jackson, Marie, additional, Kay, Clive, additional, Lowe, Andy, additional, McGowan, Janet, additional, Mohammed, Amjad, additional, Robinson, Jon, additional, Curry, Lara, additional, Maheswaran, Sasithar, additional, Ramesh, Subramanian, additional, Riddle, Pippa, additional, Balogun, Shaki, additional, Campbell, Yvonne, additional, Jeyadevan, Nelesh, additional, Kavidasan, Aji, additional, Locke, Imogen, additional, Loke, Tuck-Kay, additional, Olaleye, Ibiyemi, additional, Collins, Clare, additional, Green, Elizabeth, additional, Prendergast, Colm, additional, Win, Thida, additional, Davis, Amy, additional, Blakeway, Lyn, additional, Gourtsoyianni, Sofia, additional, Green, Adrian, additional, Kelly-Morland, Christian, additional, Naaseri, Sahar, additional, Prezzi, Davide, additional, Snell, David, additional, Boisfer, Dorothee, additional, Desai, Keyury, additional, Hans, Balinder, additional, Hans, Sophia, additional, Ntala, Eleni, additional, Alam, Adnam, additional, Burke, Stephen, additional, Bhowmik, Angshu, additional, Bharwani, Nishat, additional, Hanid, Gule, additional, Honeyfield, Lesley, additional, Stoycheva, Tina, additional, Strickland, Nicola, additional, Bazari, Farid, additional, Beedham, Helen, additional, De Los, Jane, additional, Lauigan, Reyes, additional, Limbu, Priya, additional, Lucas, Nicola, additional, O'Connor, Sally, additional, Rhodes, Anita, additional, Agoramoorthy, Laletha, additional, Handousa, Martha, additional, Jalloh, Abel, additional, Stegner, Stefania, additional, Wilson, Shanna, additional, Birch, David, additional, Chukundah, Suzanne, additional, Phiri, Priscilla, additional, Srirajaskanthan, Raj, additional, Karapanagiotou, Eleni, additional, Smith, Daniel, additional, Syeed, Ferrial, additional, van Someren, Chloe, additional, Borgstein, Rudi, additional, Roehrig, Jamila, additional, Chao, David, additional, Hurl, Lorraine, additional, Gogbashian, Andrew, additional, Nunes, Andre, additional, Simcock, Ian, additional, Stirling, James, additional, Beable, Richard, additional, Furneaux, Maureen, additional, Gibbons, Nicola, additional, Higginson, Antony, additional, Curtis, Howard, additional, Perry, Kitrick, additional, Amadi, Anita, additional, Hughes, Heather, additional, Patel, Prital, additional, Atkin, Gary, additional, Elton, Colin, additional, Karp, Stephen, additional, Woodrow, Lisa, additional, Yu, Dominic, additional, Khan, Sajid, additional, Rienhardt, Alistair, additional, Datt, Pooja, additional, Ilangovan, Rajapandian, additional, Jenkins, Ian, additional, Mahmud, Saba, additional, Light, Teresa, additional, Kellaway, Joanne, additional, O'Callaghan, Ann, additional, Partridge, William, additional, Daniel, Amelia, additional, Ekeowa, Ugo, additional, Long, Michael, additional, Russell, Peter, additional, Scurr, Erica, additional, Morgan, Veronica, additional, Tunariu, Nina, additional, Chang, Elizabeth, additional, Hughes, Laura, additional, Marwood, Ellice, additional, Prior, Katie, additional, Reddi, Meena, additional, Sargus, Kara, additional, Sharp, Abby, additional, Beeston, Teresita, additional, Isaac, Elizabeth, additional, Jayme, Adoracion, additional, Kalasthry, Jagadish, additional, Piga, Wivijin, additional, Rahman, Farzana, additional, Weir, Shraddha, additional, Austria, Aileen, additional, Crosbie, James, additional, Engledow, Alec, additional, McCullogh, Jonathan, additional, Obichere, Austen, additional, Shiu, Kai-Keen, additional, Wanstall, Christopher, additional, Simeon, Celia, additional, Smith, Amy, additional, Bateman, Andrew, additional, Breen, David, additional, Davis, Liane, additional, Everitt, Chris, additional, Johnson, Alice, additional, Nichols, Paul, additional, Shepherd, Beth, additional, Gilbert, Kayleigh, additional, Verjee, Azmina, additional, Saull, Michelle, additional, Wilson, Jonathan, additional, Adeniba, Rashidat, additional, Conteh, Veronica, additional, Howling, Sarah, additional, and Lock, Sara, additional

Published
2019
Full Text
View/download PDF

23. Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed non-small-cell lung cancer: the prospective Streamline L trial

Author

Taylor, Stuart A, primary, Mallett, Sue, additional, Ball, Simon, additional, Beare, Sandy, additional, Bhatnagar, Gauraang, additional, Bhowmik, Angshu, additional, Boavida, Peter, additional, Bridgewater, John, additional, Clarke, Caroline S, additional, Duggan, Marian, additional, Ellis, Steve, additional, Glynne-Jones, Robert, additional, Goh, Vicky, additional, Groves, Ashley M, additional, Hameeduddin, Ayshea, additional, Janes, Sam M, additional, Johnston, Edward W, additional, Koh, Dow-Mu, additional, Lock, Sara, additional, Miles, Anne, additional, Morris, Stephen, additional, Morton, Alison, additional, Navani, Neal, additional, Oliver, Alfred, additional, O'Shaughnessy, Terry, additional, Padhani, Anwar R, additional, Prezzi, David, additional, Punwani, Shonit, additional, Quinn, Laura, additional, Rafiee, Hameed, additional, Reczko, Krystyna, additional, Rockall, Andrea G, additional, Russell, Peter, additional, Sidhu, Harbir S, additional, Strickland, Nicola, additional, Tarver, Kathryn, additional, Teague, Jonathan, additional, Halligan, Steve, additional, Evans, Ruth, additional, Shahabuddin, Khawaja, additional, Jannapureddy, Revanth, additional, Mills-Baldock, Tina, additional, Barhate, Kishor, additional, Nagy, Zoltan, additional, Raouf, Sherif, additional, Aboagye, Akosa, additional, Anand, Girija, additional, Butawan, Rommel, additional, Hadley, Elizabeth, additional, Onajobi, Adesewa, additional, Thaha, Mohamed A, additional, Nawaz, Tanjil, additional, Norman, Catherine, additional, Rich, Nathalie, additional, Tulmuntaha, Sidra, additional, Ahmed, Shafi, additional, Lim, Louise, additional, McKirdy, Fiona, additional, Couture, Jenna, additional, Ferdous, Shahanara, additional, Julka, Payal, additional, Mohammed, Ali, additional, Pardoe, Helen, additional, Wijeyekoon, Sanjaya, additional, Van Ree, Katherine, additional, Blunt, Dominic, additional, Ricketts, William, additional, Jackson, Marie, additional, Kay, Clive, additional, Lowe, Andy, additional, McGowan, Janet, additional, Mohammed, Amjad, additional, Robinson, Jon, additional, Curry, Lara, additional, Maheswaran, Sasithar, additional, Ramesh, Subramanian, additional, Riddle, Pippa, additional, Balogun, Shaki, additional, Campbell, Yvonne, additional, Jeyadevan, Nelesh, additional, Kavidasan, Aji, additional, Locke, Imogen, additional, Loke, Tuck-Kay, additional, Olaleye, Ibiyemi, additional, Collins, Clare, additional, Green, Elizabeth, additional, Prendergast, Colm, additional, Win, Thida, additional, Davis, Amy, additional, Blakeway, Lyn, additional, Gourtsoyianni, Sofia, additional, Green, Adrian, additional, Kelly-Morland, Christian, additional, Naaseri, Sahar, additional, O'Donohue, John, additional, Snell, David, additional, Boisfer, Dorothee, additional, Desai, Keyury, additional, Hans, Balinder, additional, Hans, Sophia, additional, Ntala, Eleni, additional, Alam, Adnam, additional, Burke, Stephen, additional, Train, Matthew, additional, Bharwani, Nishat, additional, Hanid, Gule, additional, Honeyfield, Lesley, additional, Stoycheva, Tina, additional, Patel, Uday, additional, Bazari, Farid, additional, Beedham, Helen, additional, De Los, Jane, additional, Lauigan, Reyes, additional, Limbu, Priya, additional, Lucas, Nicola, additional, O'Connor, Sally, additional, Rhodes, Anita, additional, Agoramoorthy, Laletha, additional, Handousa, Martha, additional, Jalloh, Abel, additional, Stegner, Stefania, additional, Wilson, Shanna, additional, Birch, David, additional, Chukundah, Suzanne, additional, Phiri, Priscilla, additional, Srirajaskanthan, Raj, additional, Karapanagiotou, Eleni, additional, Smith, Daniel, additional, Syeed, Ferrial, additional, van Someren, Chloe, additional, Borgstein, Rudi, additional, Roehrig, Jamila, additional, Chao, David, additional, Hurl, Lorraine, additional, Gogbashian, Andrew, additional, Nunes, Andre, additional, Simcock, Ian, additional, Stirling, James, additional, Beable, Richard, additional, Furneaux, Maureen, additional, Gibbons, Nicola, additional, Higginson, Antony, additional, Curtis, Howard, additional, Perry, Kitrick, additional, Amadi, Anita, additional, Hughes, Heather, additional, Patel, Prital, additional, Atkin, Gary, additional, Elton, Colin, additional, Karp, Stephen, additional, Woodrow, Lisa, additional, Yu, Dominic, additional, Khan, Sajid, additional, Rienhardt, Alistair, additional, Datt, Pooja, additional, Ilangovan, Rajapandian, additional, Jenkins, Ian, additional, Mahmud, Saba, additional, Light, Teresa, additional, Kellaway, Joanne, additional, O'Callaghan, Ann, additional, Partridge, William, additional, Daniel, Amelia, additional, Ekeowa, Ugo, additional, Long, Michael, additional, Scurr, Erica, additional, Morgan, Veronica, additional, Tunariu, Nina, additional, Chang, Elizabeth, additional, Hughes, Laura, additional, Marwood, Ellice, additional, Prior, Katie, additional, Reddi, Meena, additional, Sargus, Kara, additional, Sharp, Abby, additional, Beeston, Teresita, additional, Isaac, Elizabeth, additional, Jayme, Adoracion, additional, Kalasthry, Jagadish, additional, Piga, Wivijin, additional, Rahman, Farzana, additional, Weir, Shraddha, additional, Austria, Aileen, additional, Crosbie, James, additional, Engledow, Alec, additional, McCullogh, Jonathan, additional, Obichere, Austen, additional, Shiu, Kai-Keen, additional, Wanstall, Christopher, additional, Simeon, Celia, additional, Smith, Amy, additional, Bateman, Andrew, additional, Breen, David, additional, Davis, Liane, additional, Everitt, Chris, additional, Johnson, Alice, additional, Nichols, Paul, additional, Shepherd, Beth, additional, Gilbert, Kayleigh, additional, Verjee, Azmina, additional, Saull, Michelle, additional, Wilson, Jonathan, additional, Adeniba, Rashidat, additional, Conteh, Veronica, additional, and Howling, Sarah, additional

Published
2019
Full Text
View/download PDF

25. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT) : an international, randomised, phase 3, non-inferiority trial

Author

Iveson, Timothy J., Kerr, Rachel S., Saunders, Mark P., Cassidy, Jim, Henrik Hollander, Niels, Tabernero, Josep, Haydon, Andrew, Glimelius, Bengt, Harkin, Andrea, Allan, Karen, McQueen, John, Scudder, Claire, Boyd, Kathleen Anne, Briggs, Andrew, Waterston, Ashita, Medley, Louise, Wilson, Charles, Ellis, Richard, Essapen, Sharadah, Dhadda, Amandeep S., Harrison, Mark, Falk, Stephen, Raouf, Sherif, Rees, Charlotte, Olesen, Rene K., Propper, David, Bridgewater, John, Azzabi, Ashraf, Farrugia, David, Webb, Andrew, Cunningham, David, Hickish, Tamas, Weaver, Andrew, Gollins, Simon, Wasan, Harpreet S., Paul, James, Iveson, Timothy J., Kerr, Rachel S., Saunders, Mark P., Cassidy, Jim, Henrik Hollander, Niels, Tabernero, Josep, Haydon, Andrew, Glimelius, Bengt, Harkin, Andrea, Allan, Karen, McQueen, John, Scudder, Claire, Boyd, Kathleen Anne, Briggs, Andrew, Waterston, Ashita, Medley, Louise, Wilson, Charles, Ellis, Richard, Essapen, Sharadah, Dhadda, Amandeep S., Harrison, Mark, Falk, Stephen, Raouf, Sherif, Rees, Charlotte, Olesen, Rene K., Propper, David, Bridgewater, John, Azzabi, Ashraf, Farrugia, David, Webb, Andrew, Cunningham, David, Hickish, Tamas, Weaver, Andrew, Gollins, Simon, Wasan, Harpreet S., and Paul, James

Abstract

Background: 6 months of oxaliplatin-containing chemotherapy is usually given as adjuvant treatment for stage 3 colorectal cancer. We investigated whether 3 months of oxaliplatin-containing chemotherapy would be non-inferior to the usual 6 months of treatment. Methods: The SCOT study was an international, randomised, phase 3, non-inferiority trial done at 244 centres. Patients aged 18 years or older with high-risk stage II and stage III colorectal cancer underwent central randomisation with minimisation for centre, choice of regimen, sex, disease site, N stage, T stage, and the starting dose of capecitabine. Patients were assigned (1: 1) to receive 3 months or 6 months of adjuvant oxaliplatin-containing chemotherapy. The chemotherapy regimens could consist of CAPOX (capecitabine and oxaliplatin) or FOLFOX (bolus and infused fluorouracil with oxaliplatin). The regimen was selected before randomisation in accordance with choices of the patient and treating physician. The primary study endpoint was disease-free survival and the non-inferiority margin was a hazard ratio of 1.13. The primary analysis was done in the intention-to-treat population and safety was assessed in patients who started study treatment. This trial is registered with ISRCTN, number ISRCTN59757862, and follow-up is continuing. Findings: 6088 patients underwent randomisation between March 27, 2008, and Nov 29, 2013. The intended treatment was FOLFOX in 1981 patients and CAPOX in 4107 patients. 3044 patients were assigned to 3 month group and 3044 were assigned to 6 month group. Nine patients in the 3 month group and 14 patients in the 6 month group did not consent for their data to be used, leaving 3035 patients in the 3 month group and 3030 patients in the 6 month group for the intention-to-treat analyses. At the cutoff date for analysis, there had been 1482 disease-free survival events, with 740 in the 3 month group and 742 in the 6 month group. 3 year disease-free survival was 76.7% (95% CI 75.1-78.

Published
2018
Full Text
View/download PDF

26. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial

Author

Iveson, Timothy J, primary, Kerr, Rachel S, additional, Saunders, Mark P, additional, Cassidy, Jim, additional, Hollander, Niels Henrik, additional, Tabernero, Josep, additional, Haydon, Andrew, additional, Glimelius, Bengt, additional, Harkin, Andrea, additional, Allan, Karen, additional, McQueen, John, additional, Scudder, Claire, additional, Boyd, Kathleen Anne, additional, Briggs, Andrew, additional, Waterston, Ashita, additional, Medley, Louise, additional, Wilson, Charles, additional, Ellis, Richard, additional, Essapen, Sharadah, additional, Dhadda, Amandeep S, additional, Harrison, Mark, additional, Falk, Stephen, additional, Raouf, Sherif, additional, Rees, Charlotte, additional, Olesen, Rene K, additional, Propper, David, additional, Bridgewater, John, additional, Azzabi, Ashraf, additional, Farrugia, David, additional, Webb, Andrew, additional, Cunningham, David, additional, Hickish, Tamas, additional, Weaver, Andrew, additional, Gollins, Simon, additional, Wasan, Harpreet S, additional, and Paul, James, additional

Published
2018
Full Text
View/download PDF

27. SCOT: Tumor sidedness and the influence of chemotherapy duration on DFS.

Author

Saunders, Mark P., primary, Paul, James, additional, Crosby, Jana, additional, Brown, Gordon, additional, Iveson, Timothy, additional, Kerr, Rachel, additional, Harkin, Andrea, additional, Allan, Karen, additional, McQueen, John, additional, Pearson, Sarah R, additional, Cassidy, James, additional, Medley, Louise C., additional, Raouf, Sherif, additional, Harrison, Mark, additional, Brewster, Alison, additional, Rees, Charlotte, additional, Ellis, Richard, additional, Thomas, Anne L., additional, Churn, Mark, additional, and Maka, Noori, additional

Published
2018
Full Text
View/download PDF

28. Final DFS results of the SCOT study: An international phase III randomised (1:1) non-inferiority trial comparing 3 versus 6 months of oxaliplatin based adjuvant chemotherapy for colorectal cancer.

Author

Iveson, Timothy, primary, Kerr, Rachel, additional, Saunders, Mark P., additional, Hollander, Niels Henrik, additional, Tabernero, Josep, additional, Haydon, Andrew Mark, additional, Glimelius, Bengt, additional, Harkin, Andrea, additional, Scudder, Claire, additional, Boyd, Kathleen, additional, Waterston, Ashita Marie, additional, Medley, Louise C., additional, Wilson, Charles, additional, Ellis, Richard, additional, Essapen, Sharadah, additional, Dhadda, Amandeep Singh, additional, Harrison, Mark, additional, Falk, Stephen, additional, Raouf, Sherif, additional, and Paul, James, additional

Published
2017
Full Text
View/download PDF

29. Toxicity and quality of life data from SCOT : An international phase III randomized (1:1) noninferiority trial comparing 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy.

Author

Iveson, Timothy, Kerr, Rachel, Saunders, Mark P., Waterston, Ashita Marie, Hollander, Niels Henrik, Medley, Louise C., Tabernero, Josep, Wilson, Charles, Ellis, Richard, Essapen, Sharadah, Haydon, Andrew Mark, Dhadda, Amandeep Singh, Hughes, Robert, Falk, Stephen, Abdel-Raouf, Sherif, Glimelius, Bengt, Allan, Karen, Barlow, Winnie, Briggs, Andrew, Paul, James, Iveson, Timothy, Kerr, Rachel, Saunders, Mark P., Waterston, Ashita Marie, Hollander, Niels Henrik, Medley, Louise C., Tabernero, Josep, Wilson, Charles, Ellis, Richard, Essapen, Sharadah, Haydon, Andrew Mark, Dhadda, Amandeep Singh, Hughes, Robert, Falk, Stephen, Abdel-Raouf, Sherif, Glimelius, Bengt, Allan, Karen, Barlow, Winnie, Briggs, Andrew, and Paul, James

Abstract

Meeting Abstract: 3514

Published
2015

30. Toxicity and quality of life data from SCOT: An international phase III randomized (1:1) noninferiority trial comparing 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy.

Author

Iveson, Timothy, primary, Kerr, Rachel, additional, Saunders, Mark P., additional, Waterston, Ashita Marie, additional, Hollander, Niels Henrik, additional, Medley, Louise C., additional, Tabernero, Josep, additional, Wilson, Charles, additional, Ellis, Richard, additional, Essapen, Sharadah, additional, Haydon, Andrew Mark, additional, Dhadda, Amandeep Singh, additional, Hughes, Robert, additional, Falk, Stephen, additional, Abdel-Raouf, Sherif, additional, Glimelius, Bengt, additional, Allan, Karen, additional, Barlow, Winnie, additional, Briggs, Andrew, additional, and Paul, James, additional

Published
2015
Full Text
View/download PDF

35. CASE REPORT: Encephalopathy secondary to capecitabine chemotherapy: a case report and discussion.

Author

Tipples, Karen, Kolluri, Rajeev B., and Raouf, Sherif

Subjects
PRODRUGS, BREAST cancer vaccines, NEUROTOXICOLOGY, PROGRESSIVE multifocal leukoencephalopathy, CISPLATIN, ARTICULATION disorders
Abstract

Introduction. Capecitabine is an oral prodrug of 5-fluorouracil (5-FU) chemotherapy and is licenced for the treatment of breast and gastrointestinal cancers. Multifocal inflammatory leukoencephalopathy has been associated with intravenous 5-FU, but only a few cases of capecitabine-induced encephalopathy have been reported. Setting. We describe here a case of encephalopathy following administration of Epirubicin/ Cisplatin/Capecitabine chemotherapy, review those cases previously described and suggest recommendations for management. Results. Symptoms of neurotoxicity from 5-FU and capecitabine usually include confusion, ataxia, nystagmus, dysarthria, sensory loss, and memory loss. Withdrawal of the drug generally leads to improvement of symptoms and steroids are of only questionable benefit. Conclusion. Patients on fluouropyrimidine drugs with new neurological symptoms should be investigated with brain MRI scan and the drug should be withdrawn until symptoms resolve. Dihydropyrimidine dehydrogenase deficiency should be excluded and ideally an alternative chemotherapy regime sought. We would encourage reporting of such incidences to gain a clearer picture of the incidence and optimal management. [ABSTRACT FROM AUTHOR]

Published
2009
Full Text
View/download PDF

37. The use of pembrolizumab monotherapy for the management of head and neck squamous cell carcinoma (HNSCC) in the UK.

Author

Vasiliadou I, Grose D, Wilson C, Thapa A, Donnelly O, Lee E, Leslie I, Karim M, Hartley A, Partridge S, Medlow K, De Boisanger J, Metcalf R, Williamson A, Haridass A, Noble D, Mactier K, Walter H, Ma N, De Winton E, Cohen J, Rayner L, Geropantas K, Jankowska P, Mason J, Moleron R, Laws K, Ulahannan D, Nallathambi C, Michaelidou A, Nallamilli S, Raouf S, Palmer K, Bienz M, Karet T, Khalique S, Paterson C, Harrington K, Bhide S, and Kong A

Subjects
Humans, Male, Female, Middle Aged, Aged, Retrospective Studies, United Kingdom epidemiology, Adult, Aged, 80 and over, Antineoplastic Agents, Immunological therapeutic use, Antineoplastic Agents, Immunological adverse effects, Progression-Free Survival, Antibodies, Monoclonal, Humanized therapeutic use, Antibodies, Monoclonal, Humanized adverse effects, Squamous Cell Carcinoma of Head and Neck drug therapy, Squamous Cell Carcinoma of Head and Neck mortality, Head and Neck Neoplasms drug therapy, Head and Neck Neoplasms pathology, Head and Neck Neoplasms mortality
Abstract

Pembrolizumab has received approval in the UK as first-line monotherapy for recurrent and/or metastatic HNSCC (R/M HNSCC) following the results of the KEYNOTE-048 trial, which demonstrated a longer overall survival (OS) in comparison to the EXTREME chemotherapy regimen in patients with a combined positive score (CPS) ≥1. In this article, we provide retrospective real-world data on the role of pembrolizumab monotherapy as first-line systemic therapy for HNSCC across 18 centers in the UK from March 20, 2020 to May 31, 2021. 211 patients were included, and in the efficacy analysis, the objective response rate (ORR) was 24.7%, the median progression-free survival (PFS) was 4.8 months (95% confidence interval [CI]: 3.6-6.1), and the median OS was 10.8 months (95% CI 9.0-12.5). Pembrolizumab monotherapy was well tolerated, with 18 patients having to stop treatment owing to immune-related adverse events (irAEs). 53 patients proceeded to second-line treatment with a median PFS2 of 10.2 months (95% CI: 8.8-11.5). Moreover, patients with documented irAEs had a statistically significant longer median PFS (11.3 vs. 3.3 months; log-rank p value = <.001) and median OS (18.8 vs. 8.9 months; log-rank p value <.001). The efficacy and safety of pembrolizumab first-line monotherapy for HNSCC has been validated using real-world data., (© 2024 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results